RECOGNISE V4.0
Research type
Research Study
Full title
Description and characterisation of asthmatics eligible for biologic therapy referral among primary and secondary care settings in Europe (RECOGNISE study). An observational, multinational, cross-sectional study to describe the proportion and characteristics of severe asthma patients eligible for referral for biologic therapy in primary and secondary care settings in Europe
IRAS ID
249714
Contact name
Dermot Ryan
Contact email
Sponsor organisation
AstraZeneca PLC
Clinicaltrials.gov Identifier
NCT03629782, NCT
Duration of Study in the UK
0 years, 3 months, 31 days
Research summary
Asthma is a chronic inflammatory disease that is estimated to affect 300 million people globally, resulting in a significant burden to healthcare systems and society. Patients typically have respiratory symptoms including wheeze, shortness of breath, chest tightness and cough, together with variable expiratory airflow limitation. Whilst most patients with asthma can be effectively treated with currently available pharmacological therapies, meaning their asthma is well controlled with few troublesome symptoms, a subset of patients have severe asthma which is difficult-to-treat and accounts for a relatively large proportion of asthma-associated morbidity and healthcare costs.
REC name
London - West London & GTAC Research Ethics Committee
REC reference
18/LO/1795
Date of REC Opinion
3 Oct 2018
REC opinion
Unfavourable Opinion